Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/20531
Title: Oral artesunate dose-response relationship in acute falciparum malaria
Authors: Brian J. Angus
Itaporn Thaiaporn
Kenechanh Chanthapadith
Yupin Suputtamongkol
Nicholas J. White
Mahidol University
Keywords: Medicine;Pharmacology, Toxicology and Pharmaceutics
Issue Date: 28-Feb-2002
Citation: Antimicrobial Agents and Chemotherapy. Vol.46, No.3 (2002), 778-782
Abstract: The combination of an oral artemisinin derivative (usually artesunate) and mefloquine has become standard treatment for multidrug-resistant falciparum malaria in several parts of Southeast Asia. The doses of artesunate used in monotherapy and combination treatment have largely been derived empirically. In order to characterize the in vivo dose-response relationship for artesunate and thus rationalize dosing, 47 adult patients with acute uncomplicated falciparum malaria and parasitemia ≥1% were randomized to receive a single oral dose of artesunate varying between 0 and 250 mg together with a curative dose of oral mefloquine. Acceleration of parasite clearance was used as the pharmacodynamic variable. An inhibitory sigmoidal maximum effect (Emax) pharmacodynamic model typical of a dose-response curve was fitted to the relationship between dose and shortening of parasite clearance time (PCT). The Emaxwas estimated as 28.6 h, and the 50% effective concentration was 1.6 mg/kg of body weight. These results imply that there is no reduction in PCTs with the use of single oral doses of artesunate higher than 2 mg/kg, and this therefore reflects the average lower limit of the maximally effective dose.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0036168512&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/20531
ISSN: 00664804
Appears in Collections:Scopus 2001-2005

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.